Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (261-270 of 311) with videos related to

Pageof 32
Sort By:
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
BMC Cancer|April 17, 2013
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyAlain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, et al.
JAMA Oncology|April 15, 2016
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical TrialAhmad Awada, Ramon Colomer, Kenichi Inoue, et al.
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJavier Cortes, Linda Vahdat, Joanne L Blum, et al.
British Journal of Cancer|November 24, 2020
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T J van Bussel, Ahmad Awada, Maja J A de Jonge, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Journal for Immunotherapy of Cancer|May 24, 2025
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trialJérémy Blanc, Aurélien Carnot, Philippe Barthélémy, et al.
BMC Cancer|April 17, 2015
Erratum: preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyAlain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, et al.
BMC Cancer|December 3, 2021
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, et al.
Pageof 32

Showing results (261-270 of 311) with videos related to

Sort By:
Pageof 32
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
BMC Cancer|April 17, 2013
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyAlain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, et al.
JAMA Oncology|April 15, 2016
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical TrialAhmad Awada, Ramon Colomer, Kenichi Inoue, et al.
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJavier Cortes, Linda Vahdat, Joanne L Blum, et al.
British Journal of Cancer|November 24, 2020
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T J van Bussel, Ahmad Awada, Maja J A de Jonge, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Journal for Immunotherapy of Cancer|May 24, 2025
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trialJérémy Blanc, Aurélien Carnot, Philippe Barthélémy, et al.
BMC Cancer|April 17, 2015
Erratum: preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyAlain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, et al.
BMC Cancer|December 3, 2021
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, et al.
Pageof 32